C6orf35 Activators
C6orf35 Activators are a diverse array of chemical entities that serve to enhance the functional activity of C6orf35, each acting upon distinct signaling pathways or biological processes. As C6orf35's specific functions and pathways are not well-characterized, the following narrative is a logical extension based on the involvement of C6orf35 in cellular processes, given the lack of direct activators. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), through PI3K activation, may indirectly lead to the enhancement of C6orf35 by promoting cell survival signaling, which could be a process where C6orf35 is potentially involved. Forskolin might elevate intracellular cAMP levels, thus activating protein kinase A (PKA), which could phosphorylate substrates and proteins associated with pathways in which C6orf35 may function. This would enhance the activity of C6orf35 by promoting a favorable phosphorylation environment. Similarly, agents that increase intracellular calcium, such as ionomycin, may indirectly enhance C6orf35 activity by activating calcium-dependent proteins and enzymes, potentially interconnected with C6orf35-mediated pathways.
Furthermore, molecules such as cyclic guanosine monophosphate (cGMP) and nitric oxide (NO) donors, which signal through cGMP-dependent protein kinases or modulate vasodilation, could indirectly increase the activity of C6orf35 by affecting pathways where its action is beneficial for cellular responses to stress or vascular events. Phorbol 12-myristate 13-acetate (PMA), by activating protein kinase C (PKC), could influence signaling cascades that lead to the activation of processes where C6orf35 is a participant. Additionally, compounds that mimic the action of growth factors, such as epidermal growth factor (EGF) mimetics, may activate receptor tyrosine kinases and downstream signaling, conceivably leading to the enhancement of C6orf35's role in these pathways. Lastly, molecules that modulate G-protein coupled receptor (GPCR) signaling, such as GPCR agonists or allosteric modulators, could enhance C6orf35 activity by influencing the signaling pathways to which C6orf35 is contributory, thereby adjusting cellular responses that could involve C6orf35.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
A calcium ionophore that increases intracellular calcium levels, potentially activating calcium-dependent signaling pathways that could intersect with those regulated by C6orf35, resulting in its indirect activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
A potent activator of protein kinase C (PKC) that modulates various signaling pathways. PKC activation could lead to phosphorylation of proteins in pathways where C6orf35 is involved, thereby enhancing its activity. | ||||||
Spectinomycin dihydrochloride pentahydrate | 22189-32-8 | sc-203279 sc-203279A | 5 g 10 g | $84.00 $122.00 | 9 | |
A nitric oxide (NO) donor that may influence signaling pathways through cGMP-dependent kinases or modify vasodilatory responses. This effect could indirectly enhance the activity of C6orf35 if it is part of NO-mediated signaling events. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A polyphenol found in green tea that has been shown to modulate kinase activity. Its effects on signal transduction could lead to an indirect enhancement of C6orf35 activity if it is involved in pathways affected by EGCG. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, which could shift signaling dynamics in favor of pathways that involve C6orf35, thus potentially enhancing its activity indirectly. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAP kinase, which may alter the signaling balance to favor pathways where C6orf35 plays a role, potentially resulting in enhanced activity of C6orf35. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, which could modify downstream signaling pathways, potentially increasing the functional activity of C6orf35 indirectly by affecting signaling networks where it is a part. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that could impact signaling pathways involving C6orf35, leading to its indirect activation through alteration of the signaling milieu. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
A membrane-permeable cAMP analog that activates PKA, potentially enhancing the activity of C6orf35 by promoting phosphorylation in pathways where it is involved. | ||||||